AIRLINK 74.64 Decreased By ▼ -0.21 (-0.28%)
BOP 5.01 Increased By ▲ 0.03 (0.6%)
CNERGY 4.51 Increased By ▲ 0.02 (0.45%)
DFML 42.44 Increased By ▲ 2.44 (6.1%)
DGKC 87.02 Increased By ▲ 0.67 (0.78%)
FCCL 21.58 Increased By ▲ 0.22 (1.03%)
FFBL 33.54 Decreased By ▼ -0.31 (-0.92%)
FFL 9.66 Decreased By ▼ -0.06 (-0.62%)
GGL 10.43 Decreased By ▼ -0.02 (-0.19%)
HBL 114.29 Increased By ▲ 1.55 (1.37%)
HUBC 139.94 Increased By ▲ 2.50 (1.82%)
HUMNL 12.25 Increased By ▲ 0.83 (7.27%)
KEL 5.21 Decreased By ▼ -0.07 (-1.33%)
KOSM 4.50 Decreased By ▼ -0.13 (-2.81%)
MLCF 38.09 Increased By ▲ 0.29 (0.77%)
OGDC 139.16 Decreased By ▼ -0.34 (-0.24%)
PAEL 25.87 Increased By ▲ 0.26 (1.02%)
PIAA 22.20 Increased By ▲ 1.52 (7.35%)
PIBTL 6.80 No Change ▼ 0.00 (0%)
PPL 123.58 Increased By ▲ 1.38 (1.13%)
PRL 26.81 Increased By ▲ 0.23 (0.87%)
PTC 14.01 Decreased By ▼ -0.04 (-0.28%)
SEARL 58.53 Decreased By ▼ -0.45 (-0.76%)
SNGP 68.01 Decreased By ▼ -0.94 (-1.36%)
SSGC 10.47 Increased By ▲ 0.17 (1.65%)
TELE 8.39 Increased By ▲ 0.01 (0.12%)
TPLP 11.05 Decreased By ▼ -0.01 (-0.09%)
TRG 63.21 Decreased By ▼ -0.98 (-1.53%)
UNITY 26.59 Increased By ▲ 0.04 (0.15%)
WTL 1.42 Decreased By ▼ -0.03 (-2.07%)
BR100 7,941 Increased By 103.5 (1.32%)
BR30 25,648 Increased By 196 (0.77%)
KSE100 75,983 Increased By 868.6 (1.16%)
KSE30 24,445 Increased By 330.8 (1.37%)

Those who say ‘no good deed goes unrewarded’ have surely not paid attention to Pakistan’s pharma industry. For years, MNC players such as GlaxoSmithKline (PSX: GLAXO) have kept the momentum going, hoping that the regulator will offer an enabling environment for manufacturers to pick up steam. However, pharma’s appeals seem to have fallen on deaf ears.

In its half-yearly financial results announced this Monday, the company maintained modest growth in top-line of six percent compared to same period last year. However, production costs also grew in line, trimming gross margin by 90bps.

This should come as no surprise for industry watchers. The industry has been pleading its case with regulator for CPI-based inflation adjustment for some time. It met with some success in January this year, but its benefits seem to have not translated into profitability yet.

As if industry’s chronic challenge of price control were not enough, rupee devaluation over the last nine months has not helped company (and industry’s) fortunes either, as cost of raw material import also ballooned. Overheads also expanded at the same time, with 16 percent year-on-year growth in selling, marketing and distribution expense.

Note that in line with the industry, marketing and distribution expense constitutes up to ten percent of top-line vertically for GLAXO, which is a significant input. Of this, salaries, wages and benefit on average constitute 40 percent of this head. While the firm has maintained its good name for investing in human resource, the 16 percent growth in the head managed to wipe off an incremental Rs233 million from earnings, over and above last year.

The impact from selling, marketing & distribution was sufficient to wipe off the little expansion of Rs115 million in gross profits, compared to same period last year. As a result, profit from operations recorded a year-on-year decline of eighth percent for 1HCY18.

Despite the challenges, GLAXO’s outlook on the country remains strong. Market insiders suggest that the company is planning to shift its regional headquarters to Pakistan, as the headstrong market of 220 million people remains too big to miss, despite the slow change on the regulator front. If the news is correct, the firm’s investment and expansion plans will remain one to watch closely!

Copyright Business Recorder, 2018

Comments

Comments are closed.